NovoCure (NVCR) Debt Ratio (2015 - 2026)

NovoCure (NVCR) posted Debt Ratio of 0.25 for Q2 2026, down 0.7% sequentially from 0.25 in Q1 2026, and up 214.43% YoY from 0.08 in Q2 2025.

NovoCure (NVCR) Debt Ratio (2015 - 2026) Analysis & Trends

NovoCure has reported Debt Ratio for 12 years, with the latest figure at 0.25 in Q2 2026.

Quarterly Debt Ratio rose 214.43% year-over-year to 0.25 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.25 (up 214.43% YoY) and the FY2025 annual result came in at 0.24, up 209.24% from the prior year.
Debt Ratio slipped to 0.25 in Q2 2026 per NVCR's latest filing, from 0.25 in the prior quarter.
Over five years, Debt Ratio peaked at 0.51 in Q1 2024 and troughed at 0.08 in Q1 2025.
A 5-year average of 0.3 and a median of 0.25 in 2026 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2025 and 2026: Debt Ratio sank 84.64% in 2025, then soared 217.9% in 2026.
Over 5 years, Debt Ratio stood at 0.47 in 2022, then advanced by 4.41% to 0.5 in 2023, then tumbled by 84.17% to 0.08 in 2024, then surged by 209.24% to 0.24 in 2025, then gained by 1.59% to 0.25 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.25, 0.25, and 0.24 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	200.79 Bn	195.19 Bn	7.27 Bn	0.30
2	Stryker	125.96 Bn	122.49 Bn	4.50 Bn	0.31
3	Medtronic	118.43 Bn	109.21 Bn	6.41 Bn	0.30
4	Boston Scientific	73.13 Bn	72.59 Bn	3.85 Bn	0.28
5	Edwards Lifesciences	51.63 Bn	47.38 Bn	1.35 Bn	0.04
6	Dexcom	34.60 Bn	32.65 Bn	830.00 Mn	-
7	GE HealthCare Technologies	33.71 Bn	31.60 Bn	2.18 Bn	0.27
8	Koninklijke Philips	26.17 Bn	22.85 Bn	4.55 Bn	0.28
9	Steris	23.14 Bn	22.66 Bn	684.20 Mn	0.18
10	NovoCure	2.02 Bn	1.58 Bn	142.48 Mn	0.25

Download Data